39.16

1.10% -0.435

After Hours: 39.22 0.055 +0.14%

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $39.16, with a volume of 2.79M. It is down -1.10% in the last 24 hours and up +3.50% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$39.60

Open:

$39.5

24h Volume:

2.79M

Relative Volume:

0.66

Market Cap:

$16.73B

Revenue:

$2.31B

Net Income/Loss:

$1.66B

P/E Ratio:

17.05

EPS:

2.297

Net Cash Flow:

$827.02M

1W Performance:

-1.69%

1M Performance:

+3.50%

6M Performance:

+17.12%

1Y Performance:

+50.06%

1-Day Range:

$38.98

$39.64

1-Week Range:

$38.98

$40.50

52-Week Range:

$24.05

$41.24

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2025-02-11

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	39.16	16.92B	2.31B	1.66B	827.02M	2.297
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-25	Initiated	Goldman	Buy
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

06:03 AM

Royalty Pharma (NASDAQ:RPRX) CFO Sells $2,774,234.34 in Stock - MarketBeat

06:03 AM

05:34 AM

Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $931,686.69 in Stock - MarketBeat

05:34 AM

03:03 AM

Is Royalty Pharma plc stock a good choice for value investors2025 Market Sentiment & Verified Technical Trade Signals - Newser

03:03 AM

01:06 AM

Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com India

01:06 AM

08:46 AM

Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement - Nasdaq

08:46 AM

08:32 AM

Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria

08:32 AM

08:16 AM

Royalty Pharma, Denali Sign $275 Million Hunter Syndrome Treatment Royalty Deal - MarketScreener

08:16 AM

07:42 AM

Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com

07:42 AM

07:28 AM

Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com India

07:28 AM

07:20 AM

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative

07:20 AM

06:53 AM

OMERS ADMINISTRATION Corp Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat

06:53 AM

06:43 AM

Is Royalty Pharma plc (RPD) stock attractive post correction2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - Newser

06:43 AM

06:21 AM

How Royalty Pharma plc (RPD) stock trades pre earningsQuarterly Profit Summary & Weekly High Return Forecasts - Newser

06:21 AM

06:12 AM

How Royalty Pharma plc (RPD) stock performs in easing cyclesJuly 2025 Action & Community Consensus Stock Picks - Newser

06:12 AM

03:48 AM

Arrowstreet Capital Limited Partnership Purchases 1,615,706 Shares of Royalty Pharma PLC $RPRX - MarketBeat

03:48 AM

Dec 03, 2025

Royalty Pharma EVP Coyne sells shares worth $2.77 million By Investing.com - Investing.com Nigeria

Dec 03, 2025

Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million By Investing.com - Investing.com Nigeria

Dec 03, 2025

Transcript : Royalty Pharma plc Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 03 - MarketScreener

Dec 03, 2025

Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million - Investing.com

Dec 03, 2025

100,000 Shares in Royalty Pharma PLC $RPRX Acquired by Watchtower Advisors LP - MarketBeat

Dec 03, 2025

Norges Bank Invests $181.39 Million in Royalty Pharma PLC $RPRX - MarketBeat

Dec 03, 2025

Korea Investment CORP Sells 160,900 Shares of Royalty Pharma PLC $RPRX - MarketBeat

Dec 03, 2025

Dec 02, 2025

How Royalty Pharma plc (RPD) stock correlates with oil marketsWeekly Market Outlook & Weekly High Return Stock Opportunities - Newser

Dec 02, 2025